Kurs & Likviditet
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Medicinteknik |
2022-09-01 07:30:16
Press Release - Oslo, Norway, September 1, 2022: Photocure ASA (OSE: PHO), the
Bladder Cancer Company, today announced the appointment of Dr. Anders Neijber to
the position of Chief Medical Officer, Global Medical Affairs and Clinical
Development and R&D, effective September 1, 2022.
Dr. Neijber is Photocure's current VP Medical Affairs and Clinical Development
and joined the company in August 2021. He brings over 25 years of substantial
experience in the Uro-oncology area and successful leadership in the
pharmaceutical industry. He has had global and regional leadership roles, both
in the U.S. and Europe, within Clinical R&D and Medical Affairs, having worked
for Pfizer, AstraZeneca, Johnson & Johnson, Allergan, Ferring, and Novartis.
[Dr. Anders Neijber]
Dr. Neijber is a board-certified urologist, and has held an Assistant Professor
position at the Department of Clinical Pharmacology, Robert Wood Johnson Medical
School, New Jersey.
"In the time that Anders has been with Photocure, he has proven his ability to
apply his extensive experience and deep knowledge in the field of Urology,
together with his business acumen in leading our Global Medical Affairs
strategy" said Dan Schneider, President and Chief Executive Officer of
Photocure. "As Photocure continues to grow and expand its global reach, Medical
Affairs will have an increasingly important role in navigating the complex
health-care environment. Anders will be able to provide a strategic approach
beyond addressing the heightened regulatory and compliance regulations, to
further build a Global Medical Affairs organization that will have a strong
foundation for future scalability and capability globally."
About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com
For further information, please contact:
Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com
Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com
David Moskowitz
Vice President, Investor Relations
Photocure ASA
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com
Media and IR enquiries:
Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no